These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 6099616

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C.
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis.
    Fitzgerald DJ, Fragetta J, Fenelon LC, FitzGerald GA.
    Adv Prostaglandin Thromboxane Leukot Res; 1987 Apr; 17A():496-500. PubMed ID: 2959103
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
    Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B.
    J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
    [Abstract] [Full Text] [Related]

  • 10. [Antithrombotic agents against platelet aggregation].
    Tada M, Kuzuya T, Ohmori M.
    Nihon Rinsho; 1983 Dec; 41(12):2781-6. PubMed ID: 6687068
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B, Arnout J, Deckmyn H, Vermylen J.
    Thromb Haemost; 1993 Nov 15; 70(5):822-5. PubMed ID: 8128441
    [Abstract] [Full Text] [Related]

  • 14. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1984 Jan 15; 228(1):240-4. PubMed ID: 6319669
    [Abstract] [Full Text] [Related]

  • 15. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.
    Brittain RT, Boutal L, Carter MC, Coleman RA, Collington EW, Geisow HP, Hallett P, Hornby EJ, Humphrey PP, Jack D.
    Circulation; 1985 Dec 15; 72(6):1208-18. PubMed ID: 2998642
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
    Cerletti C, Rajtar G, Bertelé V, de Gaetano G.
    Thromb Haemost; 1984 Oct 31; 52(2):215. PubMed ID: 6441306
    [No Abstract] [Full Text] [Related]

  • 17. Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease.
    Dorn GW, Halushka PV.
    Ration Drug Ther; 1985 Jul 31; 19(7):1-7. PubMed ID: 2997839
    [No Abstract] [Full Text] [Related]

  • 18. S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect.
    De Clerck F.
    Thromb Haemost; 1986 Oct 21; 56(2):236. PubMed ID: 3810559
    [No Abstract] [Full Text] [Related]

  • 19. Clinical aspects of the arachidonic acid--thromboxane pathway.
    Mitchell JR.
    Br Med Bull; 1983 Jul 21; 39(3):289-95. PubMed ID: 6226333
    [No Abstract] [Full Text] [Related]

  • 20. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec 21; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.